Literature DB >> 24438459

The effects of zoledronic acid and dexamethasone on osseointegration of endosseous implants: histological and histomorphometrical evaluation in rats.

Marcio A de Oliveira1, Denise A Asahi1, Celey A E Silveira2, Luiz Antonio P A Lima1, Michael Glick3, Marina Gallottini1.   

Abstract

BACKGROUND: Bisphosphonates are a widely used class of drugs that prevent bone loss. Several side effects related to bisphosphonate therapy have been reported, including osteonecrosis of the jaws associated with invasive dental procedures and implants placement.
OBJECTIVES: To evaluate the influence of intravenous nitrogen-containing BPs in combination with or without dexamethasone on osseointegration of titanium implants placed in an animal model.
METHODS: Twenty-seven male Wistar rats were divided into three groups: group 1 was treated solely with zoledronic acid, group 2 was treated with zoledronic acid and dexamethasone, and group 3 did only receive saline solution injections. Two endosseous implants were placed in each tibia, and three animals from each group were sacrificed at postoperative times of seven, 14, and 28 days. Non-decalcified sections were observed with light microscopy for histological and histomorphometrical analyses.
RESULTS: Histomorphometrical analysis using the animals and the implants as unit of measurement revealed no statistically significant difference regarding bone-implant contact and bone density among the three groups. Histological observation revealed that zoledronic acid-treated animals in combination with or without dexamethasone showed expressive less bone remodeling activity at 14 and 28 days after implants placement, compared with control specimens.
CONCLUSIONS: The studied bisphosphonate regimens did not interfere with the osseointegration of the implants, cortical, or medular bone deposition, but a possible lack of bone remodeling of the original cortical bone may affect long-term osseointegration.
© 2014 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  animal model; bisphosphonates; endosseous implants

Mesh:

Substances:

Year:  2014        PMID: 24438459     DOI: 10.1111/clr.12335

Source DB:  PubMed          Journal:  Clin Oral Implants Res        ISSN: 0905-7161            Impact factor:   5.977


  4 in total

Review 1.  CBCT-based bone quality assessment: are Hounsfield units applicable?

Authors:  R Pauwels; R Jacobs; S R Singer; M Mupparapu
Journal:  Dentomaxillofac Radiol       Date:  2015       Impact factor: 2.419

2.  Raloxifene but not alendronate can compensate the impaired osseointegration in osteoporotic rats.

Authors:  Leonardo Perez Faverani; Tárik Ocon Braga Polo; Gabriel Ramalho-Ferreira; Gustavo Antonio Correa Momesso; Jaqueline Suemi Hassumi; Ana Cláudia Rossi; Alexandre Rodrigues Freire; Felippe Bevilacqua Prado; Eloá Rodrigues Luvizuto; Reinhard Gruber; Roberta Okamoto
Journal:  Clin Oral Investig       Date:  2017-03-29       Impact factor: 3.573

3.  Zoledronic acid inhibits osteoclastogenesis and bone resorptive function by suppressing RANKL‑mediated NF‑κB and JNK and their downstream signalling pathways.

Authors:  Xiao-Lin Huang; Chao Liu; Xue-Mei Shi; Yu-Ting Cheng; Qian Zhou; Jian-Ping Li; Jian Liao
Journal:  Mol Med Rep       Date:  2021-12-22       Impact factor: 2.952

Review 4.  Effects of Systemic or Local Administration of Zoledronate on Implant Osseointegration: A Preclinical Meta-Analysis.

Authors:  Yao He; Wei Bao; Xiang-Dong Wu; Wei Huang; Hong Chen; Zhengyun Li
Journal:  Biomed Res Int       Date:  2019-09-22       Impact factor: 3.411

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.